HDAC9 and cancer: Our results caution against the use of HDAC inhibitors as front-line therapies in pregnant women diagnosed with cancer due to possible effects on placental function, and highlight the possibility of using clinically approved HDAC inhibitors in specific obstetric pathologies characterized by aberrant cytotrophoblast differentiation.